Stevanato Group S.p.A.

NYSE:STVN

Medical - Instruments & Supplies

Healthcare
$15.36 +3.90%

+$0.67 today

Market cap
$4.20B
Beta
0.78
P/E (TTM)
29.9
EPS (TTM)
$0.52
Dividend yield
0.35%
52W Low $12.89High $28.00

Volume 0.61M

Average 0.52M

STVN Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Stevanato Group S.p.A.NYSE: STVN

Net Margin · Q2 FY2026 · quarter ended Jun 2026

Net margin narrows to 7.6%

Net margin was 7.6% in Q2 FY2026, down 3.0 pp from a year earlier. On a trailing-twelve-month basis it was 11.0%, down 0.8 pp year over year. Over 3 fiscal years it narrowed by 2.7 pp.

Context

  • Net margin widened in 1 of the last 3 fiscal years.

What to watch

Whether net margin reaches the consensus estimate from 10 analysts of 11.9% for the fiscal year ending Dec 2026, up from 11.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
7.6%-2.6 pp QoQ
Last fiscal yearDec 2025
11.8%+1.1 pp YoY
LTMJun 2026
11.0%-0.8 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-3.0 pp+1.4 pp+4.4 pp
1 year+1.1 pp+0.2 pp-1.0 pp
3 years-2.7 pp+1.6 pp+4.4 pp
5 years+7.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
11.8%
Year-over-year change
+1.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How STVN compares with its peers on the latest reported figures

  • STVN's LTM Jun 2026 net margin of 11.0% is the highest of the 10 companies compared; the peer median is 2.2%.
  • Its year-over-year change of -0.8 pp is the 6th highest of 10, against a peer median of +1.2 pp.
  • Over three fiscal years its change of -2.7 pp compares with a peer median of -1.2 pp.
STVN Competitors Peer median
Net Margin for STVN and competitors
Company Period LTM level YoY 3-year change
STVNStevanato Group S.p.A.LTM Jun 202611.0% -0.8 pp-2.7 pp
CHEChemed CorporationLTM Jun 202610.6% -1.0 pp-1.2 pp
MMSIMerit Medical Systems, Inc.LTM Sep 20269.9% +1.9 pp+2.0 pp
ATRAptarGroup, Inc.LTM Jun 20269.2% -1.6 pp+3.2 pp
MASIMasimo CorporationLTM Apr 20264.9% +32.0 pp-17.0 pp
BTSGBrightSpring Health Services, Inc. Common StockLTM Sep 20262.2% +1.2 pp+2.2 pp
BLCOBausch + Lomb CorporationLTM Jun 2026-3.2% +2.4 pp-7.2 pp
AVTRAvantor, Inc.LTM Jun 2026-8.8% -19.1 pp-17.2 pp
AXSMAxsome Therapeutics, Inc.LTM Jun 2026-24.7% +25.2 pp+345.3 pp
TFXTeleflex IncorporatedLTM Jun 2026-39.6% -45.9 pp-58.5 pp
NUVLNuvalent, Inc.FY2025— ——
Peer median (excluding STVN) 2.2%+1.2 pp-1.2 pp

Competitors are the stored peer set for STVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue843.92M983.68M1.09B1.1B1.14B
Cost of Revenue578.52M663.88M745.46M801.72M809.15M
Gross Profit265.41M319.8M339.89M302.32M330.33M
Gross Margin31.4%32.5%31.3%27.4%29.0%
Research & Development29.62M34.39M35.67M31.67M24.4M
Selling, General & Admin82.95M111.83M113.92M118.6M122.85M
Operating Expenses103.18M127.37M139.17M141.18M147.25M
Depreciation & Amortization56.38M64.82M78.48M80.65M88.57M
EBITDA226.93M256.4M272.35M247.8M292.01M
EBITDA Margin26.9%26.1%25.1%22.4%25.6%
Operating Income162.23M192.43M200.72M161.14M183.08M
Operating Margin19.2%19.6%18.5%14.6%16.1%
Interest Income548K648K792K1.72M12.49M
Interest Expense4.87M3.94M4.32M6.86M21.8M
Other Income / Expenses3.45M(4.79M)(11.17M)(854K)(1.44M)
Income Before Tax165.67M187.64M189.55M160.29M181.64M
Pre-Tax Margin19.6%19.1%17.5%14.5%15.9%
Income Tax Expense31.4M44.63M43.86M42.52M47.35M
Net Income134.32M142.85M145.63M117.78M134.28M
Net Margin15.9%14.5%13.4%10.7%11.8%
EPS (Basic)0.530.530.550.430.49
EPS (Diluted)0.530.530.550.430.49
Weighted Avg Shares264.7M264.7M264.95M272.87M273M
Weighted Avg Shares (Diluted)264.7M264.7M264.98M272.88M273M

Stevanato Group S.p.A.

NYSE:STVN

Intrinsic Alpha fair value

Locked

Current Price

$15.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.